PRR13P4

Across TCGA pan-cancer cohorts, PRR13P4 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PRR13P4’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PRR13P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRR13P4 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

LIHC, THCA, and LUSC are the cancer types where PRR13P4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRR13P4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.065	.012	3	view →
THCA	Male	All	−0.154	<.001	2	view →
LUSC	All	II,III,IV	+0.054	.004	2	view →
BRCA	Female	All	+0.037	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PRR13P4–LIHC

Open the LIHC breakdown →